ExecRank Honors David Jin, M.D., Ph.D. of BioTime Inc. as a Top Chief
Medical Officer for 2012
SAN FRANCISCO -- March 18, 2013
David Jin, M.D., Ph.D., Chief Medical Officer, at BioTime Inc. (NYSE/AMEX:
BTX) has been selected by ExecRank as a “Top Chief Medical Officer” for 2012.
The rankings are the result of 2-years of research and feedback from
evaluation committees and top Chief Medical Officers that yielded an algorithm
for how to rank Medical Executives based on their performance in 24 key areas.
According to Adam Navrozally, Lead Analyst for the rankings division of
ExecRank, “Dr. Jin has a long record of success in strategic research and
development, while complying with increasingly strict regulatory standards.
His strong record of success in both academic presentations and research
publications makes him a strong asset to BioTime. He is highly regarded in his
field, and amongst other Chief Medical Officers.”
According to Dr. Jin, “It is truly an honor to be elected by my peers, and
recognized by ExecRank, as a Top Chief Medical Officer for 2012. I share this
achievement with my colleagues at BioTime and our subsidiaries who support me
and the corporation. The award has motivated me to continue to work toward
achieving the best practices in the field of stem cell and regenerative
For the complete rankings, please visit www.ExecRank.com.
About Dr. Jin
Dr. David Jin became the Chief Medical Office for BioTime Inc. as well as its
two subsidiaries, namely BioTime Asia Limited and OncoCyte Corporation since
2010. Dr. Jin is a licensed physician in the U.S. who has over 15 years of
diverse experience in clinical trials, strategic consulting, regulatory
affairs, and biotechnology development. After graduating as class
valedictorian with summa cum laude distinction from Massachusetts College of
Pharmacy in 1992, Dr. Jin further obtained a combined M.D. and Ph.D. degrees
from the State University of New York Downstate College of Medicine. He
completed his clinical training in internal medicine, hematology, and oncology
at New York-Presbyterian Hospital (the teaching hospital for Columbia and
Cornell University School of Medicine), and subsequently became clinical and
research faculty at Cornell. During his academic tenure, Dr. Jin has directed
over 10 clinical trials at various R&D stages sponsored by major
pharmaceutical companies. He has served as senior clinician-scientist at the
Ansary Stem Cell Institute and published over 30 peer-reviewed research and
clinical papers, some in prestigious journals including Nature, Nature
Medicine, Cell, and PNAS. Dr. Jin has worked for the U.S. Food and Drug
Administration as medical reviewer for oncology product development. Recently,
Dr. Jin has been appointed by China’s Ministry of Health as external adviser
and member of the evaluation committee for MOH’s Third Category Medical
Treatment Technology (for regulation and standardization of stem cell therapy
and cell-based immunotherapy), as well as adviser to the Chinese-UK “Dynasty
Project” to establish an international collaborative zone for clinical
medicine in Wuhan BioLake.
Adam Navrozally, 415-578-7426 ext. 130
Press spacebar to pause and continue. Press esc to stop.